#ESMO26 在接受 EV+pembrolizumab 治疗的顺铂不适用 la/mUC 患者中，7年时仍存活者接近三分之一——EV-103 成熟数据（N=121；中位随访时间64.2个月）。
🔹 ORR 66.9%；中位 DOR 29.6个月
🔹 41%的应答者在4年时仍维持缓解
🔹 中位 OS 27.7个月；7年 OS 28.2%
🔹 ≥3级 TRAEs 64.5%；停用任一药物的比例为50.4%
🔹 未发现新的安全性信号
在顺铂不适用的 la/mUC 中展现出令人瞩目的长尾生存现象，进一步支持将 EV+P 作为 1L SOC
@UroToday @myESMO
39 浏览 · 1 赞 · 1 转发 · 0 回复
NRG-GY020: Phase III randomized trial of radiation +/- MK-3475 (pembrolizumab) for newly diagnosed early-stage high intermediate risk (HIR) mismatch repair deficient (dMMR) endometrioid endometrial cancer
https://esmocongress.esmo.orgSacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgSTARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
https://esmocongress.esmo.orgEfficacy and safety of lifileucel and pembrolizumab in patients with immune check point inhibitor-naïve advanced melanoma: Final results from IOV-COM-202 study
https://esmocongress.esmo.orgUpdated results from the phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)
https://esmocongress.esmo.orgFirst-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.org来源：Julian Chavarriaga · x.com